The trial’s primary end point was overall response rate (ORR). At the 3-year mark, the ORR was 59%, with a CR rate of 41%; both rates were maintained from prior analyses, “demonstrating the stability ...
MicroRNAs are central regulators of DLBCL biology and show strong potential as minimally invasive biomarkers to improve ...
—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...
—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...
Lyell Immunopharma has dosed the first patient in its PiNACLE – H2H Phase III chimeric antigen receptor (CAR)-cell trial for ...
BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
The median age at diagnosis was 47 years (range, 14-89). Male:female ratio was 2.5:1. Majority of the patients (69.3%) were treated in limited-resource settings. Computed tomography was used as a ...
NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced updated results from the Phase 2 EPCORE ® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results